Structure Therapeutics (NASDAQ:GPCR) Earns Peer Perform Rating from Analysts at Wolfe Research

Wolfe Research initiated coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report released on Thursday morning, Marketbeat Ratings reports. The brokerage issued a peer perform rating on the stock.

A number of other research analysts have also issued reports on the company. Guggenheim lifted their target price on Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Citizens Jmp cut their price target on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 11th. Stifel Nicolaus lifted their price objective on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Finally, Morgan Stanley boosted their price objective on Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $110.00.

Structure Therapeutics Stock Down 0.6%

Shares of GPCR opened at $45.92 on Thursday. The company has a market cap of $3.25 billion, a P/E ratio of -58.13 and a beta of -1.80. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $94.90. The firm’s 50 day moving average price is $68.79 and its 200 day moving average price is $51.60.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Research analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of GPCR. CWM LLC lifted its holdings in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 125 shares during the last quarter. HighTower Advisors LLC increased its holdings in shares of Structure Therapeutics by 3.6% in the 4th quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after acquiring an additional 320 shares during the last quarter. State of Wyoming raised its position in shares of Structure Therapeutics by 29.7% during the 4th quarter. State of Wyoming now owns 1,761 shares of the company’s stock worth $122,000 after acquiring an additional 403 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Structure Therapeutics by 9.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after acquiring an additional 413 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Structure Therapeutics by 4.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock worth $757,000 after purchasing an additional 444 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.